GPT Healthcare Q2 PAT Rises 45% as Revenue Reaches ₹136 Crore

GPT Healthcare Limited reported a 45% year-on-year rise in Q2 FY27 profit after tax to ₹15.40 crore, while revenue from operations reached ₹135.62 crore. The Kolkata-based hospital operator also improved its EBITDA margin to 19.82%, and its board declared an interim dividend of ₹1 per equity share.

What did GPT Healthcare report for Q2 FY27?

GPT Healthcare reported total income of ₹138.57 crore for the quarter ended September 30, 2026, up 15% year-on-year. Revenue from operations rose 14% to ₹135.62 crore, compared with the ₹119 crore top line reported for the corresponding quarter of the previous financial year. The reported quarterly top line was approximately ₹136 crore.

Profit after tax increased to ₹15.40 crore from ₹10.60 crore in Q2 FY26. This represented a 45% year-on-year increase. EBITDA rose 18% to ₹26.88 crore, reflecting growth in operating income and a modest improvement in profitability at the operating level.

The company operates in a single reportable segment, healthcare services in India. It has no subsidiaries or associates, and the reported financial statements are therefore standalone results. The results also indicated that operational momentum continued through the first half of FY27, with cumulative profit nearly doubling from the comparable period of FY26.

How did margins change in the September quarter?

GPT Healthcare improved its Q2 FY27 EBITDA margin to 19.82% from 19.13% in Q2 FY26. The 69-basis-point improvement accompanied the increase in revenue and EBITDA, indicating better operating efficiency during the quarter.

The margin movement is relevant because hospital operators generally depend on utilisation, case mix and cost management to improve profitability as revenue grows. GPT Healthcare had earlier indicated that it expected FY27 EBITDA margin to improve to around 21%, compared with around 19% in the previous year. Management had linked that objective to higher occupancy, lower losses at Raipur and a more favourable specialty mix.

For Q1 FY27, GPT Healthcare had reported revenue from operations of ₹126.2 crore, EBITDA of ₹26.2 crore and an EBITDA margin of 20.4%. The Q2 results show EBITDA remained above ₹26 crore, while the reported Q2 margin was slightly below the first-quarter level and above the year-earlier quarterly margin.

What dividend has GPT Healthcare declared?

GPT Healthcare declared an interim dividend of ₹1 per equity share for FY27, equal to 10% of the ₹10 face value per share. The board approved the unaudited Q2 and H1 FY27 results and the interim dividend on November 5, 2026.

The company fixed November 12, 2026 as the record date for determining shareholders eligible for the dividend. It expects the dividend payment to be completed on or before December 4, 2026. Eligibility depends on holding the shares as per the applicable record-date process.

What should investors note beyond the profit growth?

GPT Healthcare disclosed a working-capital outflow of ₹12.57 crore due to rising receivables. While the company reported higher revenue, EBITDA and profit, the receivables increase is relevant to cash conversion and collections from patients, insurers and other payers.

The working-capital movement does not change the reported Q2 profit figures, but it is an important operating metric for investors following the quality of earnings. The company has not provided further detail in the supplied information on the ageing of receivables or the specific causes of the increase.

The business has outlined capacity and operating goals in earlier communications. It operates five tertiary-care hospitals in eastern India, with 719 beds currently stated in its Q1 FY27 presentation, and has targeted a network of 1,000 beds by FY27. That presentation also stated a long-term return on capital employed objective of about 25%, alongside a focus on occupancy and average revenue per occupied bed.

What are the next events and financial targets?

GPT Healthcare scheduled an earnings conference call for November 6, 2026, at 11:00 AM IST to discuss the unaudited Q2 and H1 FY27 results. Analysts and investors will be able to seek operational updates and management commentary on the quarterly performance during that call.

The company has issued FY27 guidance for 15% overall revenue growth. Management has also previously indicated an annual EBITDA target of approximately ₹110 crore to ₹115 crore, including other income, based on an expected EBITDA margin of around 21% for FY27. These are company expectations rather than reported full-year outcomes.

For investors, the Q2 release provides evidence of year-on-year growth in revenue and profit, alongside a declared dividend. The next areas of focus include progress towards the revenue and margin guidance, the pace of expansion, and any management comments on receivable collections and cash conversion.

Conclusion

GPT Healthcare delivered higher Q2 FY27 revenue, EBITDA and net profit, with profit after tax rising 45% to ₹15.40 crore and EBITDA margin improving to 19.82%. The interim dividend of ₹1 per share adds a shareholder payout to a quarter marked by stronger operating and financial results.

The November 6 earnings call is the next scheduled event for investors. Management commentary on the FY27 15% revenue-growth guidance, the approximately 21% EBITDA-margin objective, capacity plans and the ₹12.57 crore working-capital outflow will be key points to watch.